Skip to main content
    A

    Aurinia Pharmaceuticals Inc (AUPH)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.48
    -0.25 (-1.59%)

    Market Cap: $2.11B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Aurinia Pharmaceuticals Inc (AUPH) Earnings: Report Dates and Results

    Updated Oct 30, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Aurinia Pharmaceuticals (AUPH) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Aurinia Pharmaceuticals reported EPS of $0.23, above the $0.20 estimate. It beat the EPS estimate in each of the last 9 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    60%(24/40)
    Avg Surprise
    +18.73%
    Streak
    9 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.22
    Range$0.17 - $0.25
    7 analysts
    Revenue Consensus
    $87.27M
    Range$82.71M - $91.02M
    8 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.19
    Range$0.17 - $0.21
    2 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.17+11.8%
    30d ago$0.17+11.8%
    7d ago$0.190.0%
    Current$0.19
    Revenue Consensus
    $82.95M
    Range$80.90M - $85.00M
    2 analysts

    Next Report

    AUPH has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 15.4% below the $0.26 reported for the quarter ended Dec 31, 2025.

    AUPH Earnings Call

    The latest AUPH earnings call transcript on file is labeled 2025Q4.

    Read the 2025Q4 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, AUPH beat 24, missed 13 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $83.70M, up 13.9% from $73.47M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.23$0.20N/A+15.00%Beat0.0%51 up, 2 downOct 30, 2026$83.70M
    Jun 30, 2026$0.28$0.18N/A+55.56%Beat+75.0%5N/AAug 6, 2026$83.22M
    Mar 31, 2026$0.25$0.16$0.16 - $0.25+56.25%Beat+56.3%40 up, 1 downMay 7, 2026$77.70M
    Dec 31, 2025$0.26$0.21$0.18 - $0.26+23.81%Beat+2500.0%61 up, 0 downFeb 26, 2026$77.11M
    Sep 30, 2025$0.23$0.16$0.10 - $0.21+43.75%Beat+130.0%62 up, 0 downNov 4, 2025$73.47M
    Jun 30, 2025$0.16$0.15$0.11 - $0.20+6.67%Beat+1500.0%61 up, 1 downJul 31, 2025$70.01M
    Mar 31, 2025$0.16$0.10$0.07 - $0.14+60.00%BeatN/A50 up, 1 downMay 12, 2025$62.47M
    Dec 31, 2024$0.01-$0.02-$0.09 - $0.16+162.50%BeatN/A50 up, 0 downFeb 27, 2025$59.87M
    Sep 30, 2024$0.10$0.02-$0.04 - $0.05+400.00%BeatN/A60 up, 0 downNov 7, 2024$67.77M
    Jun 30, 2024$0.01$0.01-$0.04 - $0.070.00%In lineN/A60 up, 0 downAug 1, 2024$57.19M
    Mar 31, 2024-$0.07-$0.14-$0.20 - $0.01+50.00%BeatN/A60 up, 0 downMay 2, 2024$50.30M
    Dec 31, 2023-$0.19-$0.16-$0.24 - -$0.14-18.75%MissN/A60 up, 1 downFeb 15, 2024$45.09M
    Sep 30, 2023-$0.09-$0.17-$0.19 - -$0.13+47.06%BeatN/A70 up, 0 downNov 2, 2023$54.52M
    Jun 30, 2023-$0.08-$0.19-$0.22 - -$0.16+57.89%BeatN/A60 up, 0 downAug 3, 2023$41.49M
    Mar 31, 2023-$0.18-$0.22-$0.25 - -$0.18+18.18%BeatN/A70 up, 1 downMay 4, 2023$34.41M
    Dec 31, 2022-$0.18-$0.27-$0.33 - -$0.24+33.33%BeatN/A71 up, 0 downFeb 28, 2023$28.43M
    Sep 30, 2022-$0.06-$0.19-$0.25 - $0.00+68.42%BeatN/A70 up, 0 downNov 3, 2022$55.78M
    Jun 30, 2022-$0.25-$0.22-$0.25 - -$0.19-13.64%MissN/A60 up, 0 downAug 4, 2022$28.19M
    Mar 31, 2022-$0.27-$0.27-$0.29 - -$0.240.00%In lineN/A70 up, 1 downMay 10, 2022$21.63M
    Dec 31, 2021-$0.25-$0.27-$0.30 - -$0.24+7.41%BeatN/A7N/AFeb 28, 2022$23.40M
    Sep 30, 2021-$0.39-$0.33-$0.38 - -$0.30-18.18%MissN/A7N/ANov 3, 2021$14.67M
    Jun 30, 2021-$0.37-$0.36N/A-2.78%MissN/AN/A0 up, 0 downAug 5, 2021$6.62M
    Mar 31, 2021-$0.40-$0.38N/A-5.26%MissN/AN/AN/AMay 6, 2021$914000
    Dec 31, 2020-$0.05-$0.24N/A+79.17%BeatN/AN/AN/AFeb 24, 2021$50.03M
    Sep 30, 2020-$0.30-$0.24N/A-25.00%MissN/AN/AN/ANov 10, 2020$29000
    Jun 30, 2020-$0.26-$0.24N/A-8.33%MissN/AN/AN/AAug 11, 2020$29000
    Mar 31, 2020-$0.23-$0.34N/A+32.35%BeatN/AN/AN/AMay 14, 2020$30000
    Dec 31, 2019-$0.78-$0.21N/A-271.43%MissN/AN/AN/AMar 5, 2020$29000
    Sep 30, 2019-$0.21-$0.18N/A-16.67%MissN/AN/AN/ANov 14, 2019$230000
    Jun 30, 2019-$0.17-$0.17N/A0.00%In lineN/AN/AN/AAug 6, 2019$29000
    Mar 31, 2019-$0.16-$0.18N/A+11.11%BeatN/AN/AN/AMay 14, 2019$30000
    Dec 31, 2018-$0.17-$0.18N/A+5.56%BeatN/AN/AN/AJan 22, 2019$29000
    Sep 30, 2018-$0.21-$0.19N/A-10.53%MissN/AN/AN/ANov 8, 2018$375000
    Jun 30, 2018-$0.16-$0.17N/A+5.88%BeatN/AN/AN/AAug 9, 2018$29000
    Mar 31, 2018-$0.15-$0.17-$0.20 - -$0.13+11.76%BeatN/A4N/AMay 10, 2018$30000
    Dec 31, 2017-$0.04-$0.14-$0.19 - -$0.08+71.43%BeatN/A6N/AMar 15, 2018$31000
    Sep 30, 2017-$0.16-$0.12-$0.22 - -$0.12-33.33%MissN/A4N/ANov 14, 2017$29000
    Jun 30, 2017-$0.12-$0.13-$0.14 - -$0.08+7.69%BeatN/A4N/AAug 10, 2017$329000
    Mar 31, 2017-$0.20-$0.12-$0.15 - -$0.08-66.67%MissN/A6N/AMay 15, 2017$31000
    Dec 31, 2016-$0.21-$0.11N/A-90.91%MissN/AN/AN/AJan 3, 2017$30000
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.81, up 1520.0% from the year before. It was -$0.65 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.81+1520.0%
    Dec 31, 2024$0.05N/A
    Dec 31, 2023-$0.54N/A
    Dec 31, 2022-$0.76N/A
    Dec 31, 2021-$1.41N/A
    Dec 31, 2020-$0.84N/A
    Dec 31, 2019-$1.32N/A
    Dec 31, 2018-$0.69N/A
    Dec 31, 2017-$0.52N/A
    Dec 31, 2016-$0.65N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2025Q4 for the period ended Dec 31, 2025, runs about 4,700 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2025Q4Dec 31, 20254,65810
    2025Q3Sep 30, 20253,71411
    2025Q2Jun 30, 20253,5659
    2025Q1Mar 31, 20254,02911
    2024Q4Dec 31, 20243,86010
    2024Q3Sep 30, 20243,8309
    2024Q2Jun 30, 20246,3689

    2025Q4 Earnings Call

    Opening remarks

    Peter Greenleaf CEO Good morning. We want to thank you all for joining us today to discuss Aurinia's Fourth Quarter and Full Year 2025 Update. Joining me on the call today are Joe Miller, our Chief Financial Officer; and Dr. Greg Keenan, our Chief Medical Officer. On today's call, we will report fourth quarter and full year 2025 financial results and provide an update on recent business progress. During today's call, we may make forward-looking statements based on current expectations. These forward-looking statements are subject to a number of significant risks and uncertainties, and actual results may differ materially. We are pleased to have delivered strong LUPKYNIS sales in 2025, growing at a rate of 25% year-over-year. And for 2026, we expect net product sales of $305 million to $315 million, up 12% to 16% compared to 2025. And with that introduction, I'd like to now turn the call over to Joe to review our financial results. Joe?

    Joseph Miller CFO Thank you, Peter. Total revenue for the fourth quarter of 2025 was $77.1 million, up 29% compared to $59.9 million for the same period of 2024. Net product sales of LUPKYNIS for the fourth quarter of 2025 were $74.2 million, up 29% compared to $57.6 million in 2024. Net income for the fourth quarter of 2025 was $210.8 million, up 14,957% from $1.4 million in 2024. In the fourth quarter of 2025, the company recorded an income tax benefit of $175.1 million, primarily due to the release of its valuation allowance on deferred tax assets that the company now expects to realize. Net income before income taxes for the fourth quarter of 2025 was $35.7 million, up 2,875% from $1.2 million in 2024. Diluted earnings per share for the fourth quarter of 2025 was $1.53, up 15,200% from $0.01 in 2024. Lastly, cash flows from operating activities for the fourth quarter of 2025 were $45.7 million, up 52% from $30.1 million in 2024. Total revenue for the year ended December 31, 2025, was $283.1 million, up 20% compared to the $235.1 million for the same period of 2024. As a reminder, the 2024 period included a milestone payment of $10 million associated with LUPKYNIS regulatory approval in Japan. Excluding the one-time milestone, total revenue increased by 26% over the same period in 2024. Net product sales of LUPKYNIS for the year ended December 31, 2025, were $271.3 million, up 25% from $216.2 million in 2024. Net income for the year ended December 31, 2025, was $287.2 million, up 4,852% from $5.8 million in 2024.

    Frequently Asked Questions About AUPH

    When is Aurinia Pharmaceuticals's next earnings date?

    Aurinia Pharmaceuticals's next earnings report is expected for Feb 24, 2027.

    Did AUPH beat earnings estimates last quarter?

    Yes. Aurinia Pharmaceuticals reported EPS of $0.23 for the quarter ended Sep 30, 2026, above the $0.20 estimate, a 15.00% surprise.

    What EPS do analysts expect from AUPH next quarter?

    The consensus EPS estimate for Aurinia Pharmaceuticals for the quarter ending Dec 31, 2026 is $0.22 from 7 analysts, with estimates from $0.17 to $0.25.

    How often does AUPH beat earnings estimates?

    Aurinia Pharmaceuticals beat the EPS estimate in each of the last 9 quarters, with an average surprise of +91.50%.